Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Clinical Trials in Austria / NCT06522334
Recruiting Observational

Interstitial Lung Disease Registry Study: Prospective and Retrospective Observational Study in Austria

NCT06522334 · tracked via the Priya Life Science Austria tracker
Sponsor
Ludwig Boltzmann Institute for Lung Health
Phase
Observational
Started
2024-02-28
Last updated
2025-03-14

Condition(s) studied

Interstitial Lung Disease

Study summary

The goal of this registry is to systematically record epidemiological and clinical data throughout the whole interstitial lung disease course - starting with the diagnosis, therapy, follow up of lung function, symptom control, adverse events, medication, survival and death.

There are no additional interventions regarding this registry.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * diagnosis of interstitial lung disease * written informed consent Exclusion Criteria: * to not comprehend and rightfully judge participation

Primary outcome measure(s)

  • Mortality — 10 years
    Mortality caused by interstitial lung disease
  • Loss of lung function — 2 years
    FVC and DLCO loss within 24 months

Trial sites (5)

FacilityCityRegionStatus
Klinik Hietzing Vienna Austria Recruiting
Klinik Penzing Vienna Austria Recruiting
Ludwig Boltzmann Institut for Lung Health Vienna Austria Recruiting
Klinik Ottakring Vienna Austria Recruiting
Klinik Floridsdorf Vienna Austria Recruiting

More Ludwig Boltzmann Institute for Lung Health trials in Austria

Mycobacteria Registry Study: Prospective Observational Study in Austria Recruiting
The Austrian LEAD (Lung hEart sociAl boDy) Study Active, not recruiting

Other trials for the same condition

PRospective phenotypIng and Multi-omic Endotyping of Progressive Pulmonary Fibrosis Recruiting
Efficacy and Safety Study of Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD) Recruiting
Connective Tissue Diseases and Lung Manifestations Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06522334 on ClinicalTrials.gov ↗ ← All trials in Austria